VBIV Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 23:00):

Stats
Объем за сегодня	183 338
Средний объем	460 969
Рыночная капитализация	16.32M
EPS	$0 ( 2024-04-01 )
Дата следующего отчета о доходах	( $-0.530 ) 2024-05-20
Last Dividend	$0.250 ( 2012-04-02 )
Next Dividend	$0 ( N/A )
P/E	-0.100
ATR14	$0.00600 (1.05%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-27	Dewilde Michel	Buy	35 000	Option (Right to Buy Common Shares)
2023-07-27	Braga Damian	Buy	35 000	Option (Right to Buy Common Shares)
2023-07-27	Baxter Jeff	Buy	70 000	Option (Right to Buy Common Shares)
2023-07-27	Cordeiro Joanne	Buy	35 000	Option (Right to Buy Common Shares)
2023-07-27	Beattie Nell	Buy	52 500	Option (Right to Buy Common Shares)

INSIDER POWER
-68.18
Last 96 transactions
Buy: 56 847 323 \| Sell: 16 390 901

Объем Корреляция

Длинно: -0.17 (neutral)

Кратко: 0.62 (weak)

Signal:(49.675) Neutral

VBI Vaccines Inc Корреляция

10 Самые положительные корреляции
KRON	0.879
VTSI	0.868
RUBY	0.866
ALVR	0.862
ICCC	0.849
PSTV	0.84
LSBK	0.828
GREE	0.827
POWW	0.827
PAIC	0.826

10 Самые отрицательные корреляции
SHSP	-0.85
NETE	-0.84
BOCH	-0.832
BNIXU	-0.823
RAVN	-0.803

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

VBI Vaccines Inc Корреляция - Валюта/Сырье

0.60
( weak )

0.41
( neutral )

0.00
( neutral )

-0.46
( neutral )

VBI Vaccines Inc Финансовые показатели

Annual	2023
Выручка:	$8.68M
Валовая прибыль:	$-5.82M (-66.98 %)
EPS:	$-5.96

FY	2023
Выручка:	$8.68M
Валовая прибыль:	$-5.82M (-66.98 %)
EPS:	$-5.96

FY	2022
Выручка:	$1.08M
Валовая прибыль:	$-10.19M (-942.14 %)
EPS:	$-16.37

FY	2021
Выручка:	$631 000
Валовая прибыль:	$-10.14M (-1 606.81 %)
EPS:	$-0.270

Financial Reports:

No articles found.

VBI Vaccines Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

VBI Vaccines Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.250	2003-12-18
Last Dividend	$0.250	2012-04-02
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	$1.250	--
Avg. Dividend % Per Year	0.00%	--
Score	0.23	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2027-05-31)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

0.23

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2003	$0.250	14.60%
2004	$0	0.00%
2005	$0	0.00%
2006	$0.750	16.50%
2007	$0	0.00%
2008	$0	0.00%
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0.250	0.02%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-11.81	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-1.179	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-5.05	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0.478	0.800	-2.61	-2.09	[1 - 3]
quickRatioTTM	0.329	0.800	-2.77	-2.21	[0.8 - 2.5]
cashRatioTTM	0.313	1.500	9.37	10.00	[0.2 - 2]
debtRatioTTM	0.610	-1.500	10.00	-10.00	[0 - 0.6]
interestCoverageTTM	-17.68	1.000	-7.66	-7.66	[3 - 30]
operatingCashFlowPerShareTTM	-2.51	2.00	-0.838	-1.676	[0 - 30]
freeCashFlowPerShareTTM	-2.55	2.00	-1.275	-2.55	[0 - 20]
debtEquityRatioTTM	7.05	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	-0.496	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-9.09	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-1.134	1.000	-7.41	-7.41	[0.2 - 2]
assetTurnoverTTM	0.0998	0.800	-2.67	-2.13	[0.5 - 2]
Total Score				-4.67

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.134	1.000	-0.115	0	[1 - 100]
returnOnEquityTTM	-5.05	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-2.55	2.00	-0.850	-2.55	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-2.51	2.00	-0.838	-1.676	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.00180	1.500	-3.32	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-6.93	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.85

VBI Vaccines Inc

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.